Abbott Laboratories completed the public offering and issuance of $20,000,000,000 on March 9, 2026. This constitutes entry into a material definitive agreement and creation of a direct financial obligation, as disclosed under Items 1.01 and 2.03.
Key takeaways
Abbott Laboratories completed public offering and issuance of $20,000,000,000 on March 9, 2026
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation
Exhibit 4.1: Indenture dated March 10, 2015 between Abbott Laboratories and U.S. Bank National Association